DexCom - DXCM Stock Forecast, Price & News

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last twelve months. There are currently 1 hold rating and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DXCM shares.
View DXCM analyst ratings or view top-rated stocks.

14 brokers have issued 1-year price targets for DexCom's shares. Their DXCM share price forecasts range from $83.00 to $163.75. On average, they anticipate the company's share price to reach $112.30 in the next twelve months. This suggests a possible upside of 39.2% from the stock's current price.
View analysts price targets for DXCM or view top-rated stocks among Wall Street analysts.

DexCom's stock was trading at $134.2375 at the beginning of the year. Since then, DXCM stock has decreased by 39.9% and is now trading at $80.66.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our DXCM earnings forecast.

DexCom, Inc. (NASDAQ:DXCM) announced its quarterly earnings data on Thursday, July, 28th. The medical device company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.19 by $0.02. The medical device company had revenue of $696.20 million for the quarter, compared to analysts' expectations of $709.33 million. DexCom had a trailing twelve-month return on equity of 11.79% and a net margin of 7.47%. The firm's revenue for the quarter was up 17.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.19 EPS.
Read the conference call transcript.

Shares of DexCom split on Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly issued shares were distributed to shareholders after the market closes on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

DexCom updated its FY 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.86 billion-$2.91 billion, compared to the consensus revenue estimate of $2.92 billion.

347 employees have rated DexCom Chief Executive Officer Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM), ServiceNow (NOW), Walt Disney (DIS), Trade Desk (TTD) and Shopify (SHOP).

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

DexCom's stock is owned by a variety of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (4.61%), Sands Capital Management LLC (4.56%), Jennison Associates LLC (2.18%), Clearbridge Investments LLC (1.45%), Price T Rowe Associates Inc. MD (1.04%) and UBS Asset Management Americas Inc. (1.04%). Insiders that own company stock include Andrew K Balo, Andrew K Balo, Barbara Kahn, Barry J Regan, Bridgette P Heller, Chad Patterson, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Jereme M Sylvain, Jereme M Sylvain, Kevin R Sayer, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Sadie Stern, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal.
View institutional ownership trends.

Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DXCM stock can currently be purchased for approximately $80.66.

DexCom (NASDAQ:DXCM) has a market capitalization of $31.67 billion and generates $2.45 billion in revenue each year. The medical device company earns $154.70 million in net income (profit) each year or $0.48 on an earnings per share basis.

The company employs 7,000 workers across the globe.

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The official website for the company is www.dexcom.com. The medical device company can be reached via phone at (858) 200-0200, via email at investorrelations@dexcom.com, or via fax at 858-200-0201.